Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida^®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms

References

• Zhan P, Pannecouque C, De Clercq E, Liu X. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem 2016;59:2849–78.
   PubMed Web of Science ®Google Scholar
• Namasivayam V, Vanangamudi M, Kramer VG, et al. The journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from lab to clinic. J Med Chem 2019;62:4851–83.
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT. Elsulfavirine: first global approval. Drugs 2017;77:1811–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, De Clercq E, Li G. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin Drug Metab Toxicol 2019;15:813–29.
   PubMed Web of Science ®Google Scholar
• Rai MA, Pannek S, Fichtenbaum CJ. Emerging reverse transcriptase inhibitors for HIV-1 infection. Expert Opin Emerg Drugs 2018;23:149–57.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Korsakov M, Dorogov M, et al. Probing the ‘bipolar nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Eur J Med Chem 2015;101:334–47.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Therapeutic applications of the carbonic anhydrase inhibitors. Therapy 2007;4:355–78.
   Google Scholar
  (b) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase: I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• (a) Singer M, Lopez M, Bornaghi LF, et al. Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. Bioorg Med Chem Lett 2009;19:2273–6.
   PubMed Web of Science ®Google Scholar
  (b) Angeli A, Carta F, Nocentini A, et al. Response to perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors. Biophys J 2021;120:178–81.
   PubMed Web of Science ®Google Scholar
• (a) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the α- and β-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with amines and amino acids. J Enzyme Inhib Med Chem 2018;33:227–33.
   PubMed Web of Science ®Google Scholar
  (b) Bua S, Bozdag M, Del Prete S, et al. Mono- and di-thiocarbamate inhibition studies of the δ-carbonic anhydrase TweCAδ from the marine diatom Thalassiosira weissflogii. J Enzyme Inhib Med Chem 2018;33:707–13.
   PubMed Web of Science ®Google Scholar
• (a) Menchise V, De Simone G, Alterio V, et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48:5721–7.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Mincione F, Scozzafava A, et al. Carbonic anhydrase inhibitors – part 52. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents in rabbits. Eur J Med Chem 1998;33:247–54.
   Web of Science ®Google Scholar
  (c) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102–8.
   PubMed Web of Science ®Google Scholar
  (d) Guglielmi P, Rotondi G, Secci D, et al. Novel insights on saccharin- and acesulfame-based carbonic anhydrase inhibitors: design, synthesis, modelling investigations and biological activity evaluation. J Enzyme Inhib Med Chem 2020;35:1891–905.
   PubMed Web of Science ®Google Scholar
  (e) Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem 2020;35:1462–70.
   PubMed Web of Science ®Google Scholar
• (a) Krall N, Pretto F, Decurtins W, et al. A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–5.
   PubMed Web of Science ®Google Scholar
  (b) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.
   PubMed Web of Science ®Google Scholar
  (c) Bonardi A, Nocentini A, Bua S, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. J Med Chem 2020;63:7422–44.
   PubMed Web of Science ®Google Scholar
  (d) Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99:424–31.
   PubMed Web of Science ®Google Scholar
  (e) Blandina P, Provensi G, Passani MB, et al. Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders. J Enzyme Inhib Med Chem 2020;35:1206–14.
   PubMed Web of Science ®Google Scholar
  (f) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal β-class (Cab) and γ-class (Cam) carbonic anhydrases. Curr Top Med Chem 2007;7:901–8.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Nicolae A, Popescu A. Carbonic anhydrase inhibitors: part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes. Eur J Med Chem 1996;31:431–8.
   Web of Science ®Google Scholar
  (b) Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun 2010;46:8371–3.
   PubMed Web of Science ®Google Scholar
  (c) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94.
   PubMed Web of Science ®Google Scholar
  (d) De Simone G, Langella E, Esposito D, et al. Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. J Enzyme Inhib Med Chem 2017;32:1002–11.
   PubMed Web of Science ®Google Scholar
• (a) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–9.
   PubMed Web of Science ®Google Scholar
  (b) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3.
   PubMed Web of Science ®Google Scholar
  (c) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.
   PubMed Web of Science ®Google Scholar
• (a) Alper Türkoğlu E, Şentürk M, Supuran CT, Ekinci D. Carbonic anhydrase inhibitory properties of some uracil derivatives. J Enzyme Inhib Med Chem 2017;32:74–7.
   PubMed Web of Science ®Google Scholar
  (b) Soydan E, Olcay AC, Bilir G, et al. Investigation of pesticides on honey bee carbonic anhydrase inhibition. J Enzyme Inhib Med Chem 2020;35:1923–7.
   PubMed Web of Science ®Google Scholar
• Berman HM, Battistuz T, Bhat TN, et al. The protein data bank. Acta Crystallogr D Biol Crystallogr 2002;58:899–907.
   PubMed Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comp Aided Mol Des 2013;27:221–34.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2021-1: Semiempirical NDDO protocol; Jaguar. New York (NY): MOPAC, Schrödinger, LLC; 2021.
   Google Scholar
• Harder E, Damm W, Maple J, et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 2016;12:281–96.
   PubMed Web of Science ®Google Scholar
• Greenwood JR, Calkins D, Sullivan AP, Shelley JC. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comp Aided Mol Des 2010;24:591–604.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem 2006;49:6177–96.
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Friesner RA, Xiang Z, Honig B. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 2002;320:597–608.
   PubMed Web of Science ®Google Scholar
• Cuffaro D, Nuti E, Rossello A. An overview of carbohydrate-based carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020;35:1906–22.
   PubMed Web of Science ®Google Scholar
• Bianco G, Meleddu R, Distinto S, et al. N-Acylbenzenesulfonamide Dihydro-1,3,4-oxadiazole hybrids: seeking selectivity toward carbonic anhydrase isoforms. ACS Med Chem Lett 2017;8:792–6.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8.
   PubMed Web of Science ®Google Scholar
• Schütz SG, Robinson-Papp J. HIV-related neuropathy: current perspectives. HIV AIDS 2013;5:243–51.
   Google Scholar
• Di Fiore A, Truppo E, Supuran CT, et al. Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide. Bioorg Med Chem Lett 2010;20:5023–6.
   PubMed Web of Science ®Google Scholar
• Kalinin S, Kopylov S, Tuccinardi T, et al. Lucky switcheroo: dramatic potency and selectivity improvement of imidazoline inhibitors of human carbonic anhydrase VII. ACS Med Chem Lett 2017;8:1105–9.
   PubMed Web of Science ®Google Scholar